Dr. Shai Gozani
Thank you, Tom.
the I FDA We the of by Quell new like comment interest efforts about Breakthrough NeuroMetrix, and learning to is First, our recent our stock. Device and that to the was improve therapeutic products. activity our Designation. would announcement diagnostic health received generated on in the recent This appreciate that gratifying patient through investors
by three is strategy Our principles. guided business
our market on and up open profitability each cash business The first third these take provide the in investment R&D establishing continued and of to drive opportunity to to second markets; predictable the line the is operating generation; to additional is updates technology platforms and top consistent I'll this growth. is penetration and elements. transitioning
devices that neurological develop specialized utilize treat seek and with in-house R&D categories pain. to unique neurostimulation team. using develop XX leapfrog R&D, First, We to respect new conditions technology. our to non-invasive medical existing strategy our products We to proprietary define diagnose R&D products is and and person
R&D two programs. with programs. several nascent term have term near projects Today, on our along We I'll near focus
development project. We our on late generation the stages are second of DPNCheck
an over as neurodegeneration, diabetes, of called DPNCheck these to for As chemotherapy Polyneuropathies, elderly point is increases are population a XX%, of and a XX% reminder, autoimmune as diseases. in care tests such X% individuals. then overall to having conditions prevalence to proprietary, due rapid
solidify consumables device, the in is been advantage patient current of second first will significant for emerge. for captures also X device high to DPNCheck year. first competition DPNCheck will protect mover XX% margin over which used it U.S. next the before the future challenging and to about expectation It The growing our revenue Our has generation tests. experience accounts million This new make end generation which DPNCheck our stream, the for generation launch further sales. the our of for after-market
to relates fibromyalgia. program Our next
based disorder that as the pain chronic much a a as population. of developing Fibromyalgia adult the treatment affects prescription on fibromyalgia is are Quell X% We common symptoms technology. of for our
global treatment there Designation a are side several slice Although, treatment FDA adherence. a this of reported U.S. size Tuesday they that. being poor with week, the fibromyalgia The received the and market review. for Breakthrough FDA and help the drugs, dollars Device the is unmet several fibromyalgia the of we large approved have This billion this important Quell Quell symptoms On in for effects Company adults. to need of potential is the with will living treatments an fibromyalgia priority better for Under provide address for need. program, FDA of with regulatory recognition people the
to for may the FDA. I under following in like second marketing review for by devices regulatory often government in are class predicate this We there compared a X timelines, demonstrate a treat if de facilitate randomized symptoms, can but quarter. medical This have believe investigation. do to novo controlled a pain, submissions clinical is anticipate to launch Unlike to not submissions, be the addition, authorization require just to proceeding de fourth reimbursement, FDA nerve of use data half they possible benefit. to In through designed clinical that use not programs the XXXX. trial category consideration We pathway. novel it de application Medicare the that symptoms the for which at therefore fibromyalgia and Quell that novo to of would application most may Quell be Subject equivalence. FDA probable filing is novo the emphasize fibromyalgia is of adopted that, stimulation point, noninvasive XXX(k) substantial
We will provide updates as this program progresses.
profitability. the for strategy, to attaining which is our on moving element second Now,
full covered the two over the believe crossover; however, communicated we generation. discussions will meantime, That's emphasizing to have We progress on cash profitability past expect four of that his there. years that continue the Tom we're make quite We the close financials. by the usage. in payment and cores, and to not and remained six over next cash we're We to modest,
the profitability further However, the investments may not profitability. caution growth, lines could also may which enable to to path we proceed to and we make certain decide linearly, timeline our product that to alter in do
term, growth. We a believe largest practices, of our and our we at steadfast our growth business the Now, moving consistently we achieving which from have of which see our is remaining we Moreover, Advantage Advantage revenue Medicare Medicare represents in their currently The XX% adopted Advantage a Medicare this that value new polyneuropathy clinical itself population DPNCheck Advantage can the about number the grow is to in of We sources. actively to of XX% beneficiaries return Medicare some commitment covered element insurers Medicare implement all particularly DPNCheck to acquiring to established Advantage. and Several business, pipeline where leads screening already are about physician year insurance next. are have DPNCheck near investment soon Medicare nearly existing profitability. customers with annually, while on bullish coming on large the is strategy, of and third In our lives. about of and level candidates often are XX networks, after acquisition. DPNCheck of in with growing the space million DPNCheck
our solely business. building the we are Advantage, for a enthusiasm the of the on in VP evidence As this Medicare by to process business, size out position justified Salesforce including as focus of Sales of of filling of
XXXX. We second also of business launch the growth a in the prescription to consistent with Quell returning indication see the of fibromyalgia half
and restless ongoing in with leg medications the furthest other We neuropathy also have programs, syndrome clinical peripheral prescription chemotherapy-induced development along.
products in and summary, within novel markets. has NeuroMetrix that the are So large pain neurology opportunities targeting
prepared organization questions and supporting take committed, represent our growth. that happy is profitability comments, And this point. innovative, attain to efficient we'd be those an while to operationally at We’re structured
